Baird lowered the firm’s price target on Inspire Medical (INSP) to $248 from $252 and keeps an Outperform rating on the shares. The firm said the risk/reward remains to the upside and the 2025 growth/profit outlook remains in check.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $220 from $230 at Morgan Stanley
- Inspire Medical price target lowered to $195 from $198 at Wells Fargo
- Inspire Medical Systems: Balancing Strong Performance with Operational Challenges and Regulatory Risks
- Inspire Medical Systems: Strong Buy Rating Amid Growth Prospects and DOJ Investigation Challenges
- Inspire Medical Systems Reports Strong Growth in 2024